CNS Orphan Diseases- the alternative route in CNS

Date: 09-Apr-13 to 09-Apr-13
Location: Holiday Inn Bloomsbury / London / United Kingdom
Category: Healthcare & Pharmaceuticals Technology Science Conferences & Trade Fairs

The challenges of drug development in CNS are well known with the recent failures of the large phase III trials in Alzheimer's disease illustrating the problem. There is however an alternative route in CNS which can prove to be more accessible to small and medium sized companies, and that is CNS Orphan diseases. Diseases such as Progressive Supranuclear Palsy (PSP), Fronto-Temporal Dementia (FTD) or Huntington's disease can be initial substitutes for the likes of Alzheimer's disease or Parkinson's disease in which to test the effectiveness of a drug. This timely masterclass will assess the latest challenges and potential advantages of developing drugs in CNS Orphan diseases, compared to larger CNS indications and also looks at the support that is available to drug developers in orphan diseases. Furthermore, case studies of drug companies who have followed this route will be reviewed and lessons learnt will be drawn from them to assist you with developing your own strategies.

Email: ctuna@smi-online.co.uk
Tel: +44 (0) 20 7827 6736
URL: www.smi-online.co.uk/orphan-cns6.asp

Visitors

CNS, upscaling, Alzheimer's disease, Parkinson's disease, proof of concept, orphan disease, clinical trials, orphan indications, regulatory, marketing approval, neurology, psychiatry, PSP, FTD

Exhibitors

CNS, upscaling, Alzheimer's disease, Parkinson's disease, proof of concept, orphan disease, clinical trials, orphan indications, regulatory, marketing approval, neurology, psychiatry, PSP, FTD

Go to event website